Table Of Content

Journal of Pharmacokinetics and Biopharmaceutics, Vol 23, No. 1, 1995 Author Index to Volume 22 Abrams, Steven A., 367 Leahy. D. E..4I1 Anderson, Sharon, SSI Lee, Myung G., I Anne, Suresh, 469 Lee, Sun H., 1 Au, Jessie L.>S., 183 Lefevre, Gilbert Y., 147 Lemaire, Michel, 327 Bailey, James M., IS7 Levy, Gerhard, 101 Beal, Stuart, L., 16S, 431 Louchahi, Kamel, 129 Benet, Uslie Z., 19, 97, 2S3 Lovejoy, William S., 73, S2S Bjdrkman, Sven, 381 Ludden, Thomas M., 431 Bnielisauer, Armin, 327 Ludwig, Elizabeth A., 469 Lynch, J., 411 Cardot, Jean-Michel A., 147 Chapman, Michael J., 229 Mather, Laurence E., 481 Middleton, Elliott Jr., 469 Dalton, James T., 183 Milad, Mark A., 469 Dedik, Ladislav, 293 Monro, Alastair, 41 Derendorf, Hartmut, 99 Moreau-Tod, Brigitte, 129 DuriSov4, Maria, 293 Muller, Peter, 499 Ebling, William F., 2S9, 381 Niederberger, Werner, 327 Nishimura, Koichi, S9 Finney, R. E., 411 Noe, Dennis A., S6S Garrett, Edward R., 103, 179 Gitterman, Moshe, 367 Ojingwa, Joseph C., 19 Goans, Ronald E., 367 Godbillon, Jacques A., 147 Padoin, Christophe, 129 Godfrey, Keith R., 229 Perret, Gerard, 129 Goldberg, Assaf, 449 Petitjean, Olivier, 129 Plummer, John L., 481 Hauck, Walter W., SSI Hoffman, Amnon, 449 Rescigno, AMo, 2SS Hori, Ryohei, S9 Rosner, Gary L., 499 Hu, Chuanpu, 73, S2S Rowland, Malcolm, 2S3, 327 Rutten, Albert J., 481 Iga, Tatsuji, 207 Sambol, Nancy C., I6S Jusko, William J., 469 Sawada, Yasufumi, 207 Shafer, Steven L., 73, S2S Kawai, Ryosei, 327 Sheiner, Lewis B., 431 Kawakami, Junichi, 207 Spahn-Langguth, Hildegard, 19 Kawakatsu, Kazuo, S9 Stanski, Donald R., 2S9, 381 Kim, Nak D., 1 Steimer, Jean-Louis, 327 127 009<M66X/9S/020(M)l27S07.50/0 (£> 1995 Pkngm Poblishmg Corporation 128 Tanigawara, Yusuke, 59 Wade, Janet R., 165 Taylor, D. C.. 411 Weiss, George H., 367 Tod, Michel, 129 Wientjes, M. Guillaume, 183 Upton, Richard N., 309 Yamamoto, Koujirou, 207 Vajda, Sandor, 229 Yano, Ikuko, 59 Vieira, Nancy E., 367 Yasuhara, Masato, 59 Wada, D. Russell, 259, 381 Yergey, Alfred L., 367 Journal of Pharmacokinetics and Biopharmaceutics. Vol. 23. No. I, 1995 Subject Index to Volume 22 Absorption, 411 Dosage regimen, 481 Absorption from various GI segments, 1 Dose regimen design, 73, 525 Administration rate, 481 Dose response, 449 Akaike information criterion (AIC), 431 Drug, 411 Alfentanil, 381 Drug disposition, 157 Allometry, 327 Drug distribution, 157 Anatomical and physiological properties, 207 Effect site, 525 Anesthesia, 2S9 Effector unit, 449 Anesthetics local, 481 ELISA, 147 Animal scale-up, 207 449 Enantiomers, 481 Bateman function, 103 Error, 309 Bayesian, 73, 525 Experimental design, 129 Bayesian methods, 59, 499 Bioavailability, 293 Ftest, 431 Bladder recycling, 183 Feathering, 103 Bladder resorption, 183 Fentanyl, 381 Blood cells, 327 Flip-flop k., 103 Blood flow, 259 Fluid transport, 411 Bone, 367 Frequency response, 293 Brain weight, 207 Frequency response method, 293 Bumetanide, I Bupivacaine, 481 Gentamicin, 293 Gibbs sampler, 499 Calcium kinetics, 367 Glucuronide, 19 Cancer chemotherapy, 499 Carcinogenicity, 41 Heterogeneity, 449 CD4* lymphocytes, 469 Hill coefficient, 449 CD8^ lymphocytes, 469 Human serum albumin, 19 Compartment(al) model, 73, 229, 525 Human(s), 207, 381 Computer simulation(s), 183, 259 Concentration-effect, 449 Identification, 229 Convection, 411 Indistinguishability, 229 Corticosteroids, 469 Individual bioequivalence, 551 Cortisol, 469 Initial distribution, 259 Covariate model, 165 Interspecies scaling, 327 CSF, 207 Intravenous administration, 147 Curve moments, 157 Cyclosporins, 327 Linear dynamic system, 293 Deconvolution, 259 Markov chain Monte Carlo, 499 Discrete prior, 73 Mass balance principles, 309 129 0O9O-4«6X/95/O2(KM)l29SO7.SO/O C) 1995 Plenum Publishing Corporation 130 Michaelis-Mentcn kinetics, 229 Rec-hirudin, 147 Membrane-transport limitation, 327 Regional blood flow, 381 Metacycline pharmacokinetics, 129 Renal clearance, 183 Methylprednisolone, 469 Repeated measures, 499 Model discrimination, 229 Reversible binding, 19 Model misspecification, 129 Model selection, 165, 431 Sampling time, 59 Multiple peaks, I Schwarz criterion, 431 Myelosuppression, 499 SDZ IMM, 125, 327 Shape factor, 449 New quinolones, 207 Sigmoidal Em,x model, 449 Noncompartmental analysis, 157 Small intestine, 411 Nonlinear regression, 499 Solvent-drag, 411 Nonlinear systems, 229 Species differences, 41 NONMEM, 165 Stochastic control, 73, 525 Structural model, 165 Ofloxacin, 207 Switchability, 551 Optimal sampling, 129 T-helper cells, 469 Paracellular, 411 T-suppressor cells, 469 Parameter estimation, 129 Theophylline, 59 Pharmacodynamics, 449, 469, 525 Thiopental, 259 Pharmacokinetic modeling, 259 Tissue diffusion, 381 Pharmacokinetic parameters, 207 Tissue distribution, 381 Pharmacokinetics, 1, 73, 147, 229, 309, 481, Tissue uptake, 259 525 Tolerance, 469 Phase I study, 499 Tolmetin, 19 Physiologic!al) models, 259, 381 Toxicokinetics, 41 Physiologically based pharmacokinetics, 327 Transcellular, 411 Population bioequivalence, 551 Population pharmacokinetics, 59, 165 Unit disposition function, 259 Prescribability, 551 Weighting function, 293 Rat(s), 381, 441 Receptor, 449 Zomepirac, 19 .1 t I